Medical Education Library

Once-weekly Glucagon-like Peptide-1 Receptor Agonists

This supplement is supported by funding from Novo Nordisk Inc.

 

Click Here to Read the Supplement

This supplement provides an overview of the role of once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in type 2 diabetes (T2D).

Topics include:

  • Burden of illness in patients with T2D
  • Pharmacokinetic properties and the mode and mechanism of action of GLP-1 RAs
  • Safety and clinical efficacy of GLP-1 RAs
  • Implications of cardiovascular outcomes trials in T2D

Click Here to Read the Supplement

Recommended Reading

Opioids still overprescribed for postop pain management
MDedge Family Medicine
Effects of psoriatic arthritis not just physical
MDedge Family Medicine
High testosterone in postmenopausal women may add CVD risk
MDedge Family Medicine
Renal denervation for hypertension rebounds
MDedge Family Medicine
Regular skin exams reduced advanced KCs in posttransplant patients
MDedge Family Medicine
MDedge Daily News: Group support, mentorship help combat burnout in female physicians
MDedge Family Medicine
Emergency gout admission increase is ‘call to arms’
MDedge Family Medicine
Uterine fibroids registry looks to provide comparative treatment data
MDedge Family Medicine
Psoriasis therapy with biologics not linked to increased cancer risk
MDedge Family Medicine
Emergency contraception ... and our duty to inform
MDedge Family Medicine